Breaking Finance News

A report released today by Raymond James about REGENXBIO (NASDAQ:RGNX) ups the target price to $39.00

Yesterday REGENXBIO (NASDAQ:RGNX) traded 3.56% higher at $33.70. The company’s 50-day moving average is $30.46 and its 200-day moving average is $30.46. The last stock close price is up 14.57% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 102,861 shares of the stock were exchanged, down from an average trading volume of 459,104

Indicating a possible upside of 0.16%, Raymond James bumped up the target of REGENXBIO (NASDAQ:RGNX) to $39.00

Previously on 8/17/2017, Evercore ISI reported about REGENXBIO (NASDAQ:RGNX) raised the target price from $0.00 to $25.00. At the time, this indicated a possible upside of 0.13%.

See Chart Below

REGENXBIO (NASDAQ:RGNX)

REGENXBIO has a 52 week low of $15.25 and a 52 week high of $36.10 The company’s market cap is currently $0.

About REGENXBIO (NASDAQ:RGNX)

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *